In addition to Drs. Kengatharan and Milner, Armetheon's board includes Pascal Druzgala, PhD, Co-Founder, and industry veterans, Jon Saxe and Steven P. James, formerly CEO of Labrys Biologics, Inc. (recently acquired by Teva) and KAI Pharmaceuticals, Inc. (acquired by Amgen).
Tecarfarin is being investigated for use as an oral, once-daily anticoagulant inhibitor of Vitamin K epoxide reductase (VKOR, an important enzyme in the coagulation system) which avoids CYP450-dependent metabolism and renal elimination. In a phase 2 and a phase 2/3 (EMBRACE-AC) clinical studies,this drug candidate improved time in therapeutic range (TTR) in chronically anticoagulated patients. The effect of Tecarfarin on TTR will be further investigated in the TACT clinical trial. TTR was chosen as the endpoint for these trials on the basis of evidence suggesting that better anticoagulation control (as measured by higher TTR) can protect patients from severe or even fatal adverse events. Tecarfarin is monitored using INR, and is being investigated for use without the need for CYP2C9 genotyping since Tecarfarin is not metabolized via the CYP-450 system. In pre-clinical and early clinical studies, the anticoagulant effect of Tecarfarin was reversed by existing and readily available antidotes for VKAs.
Armetheon, Inc. is a privately held San Francisco Bay area based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced, successful bi
|SOURCE Armetheon, Inc.|
Copyright©2014 PR Newswire.
All rights reserved